このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Duopharma Biotech Berhad マネジメント
マネジメント 基準チェック /44
現在、CEO に関する十分な情報がありません。
主要情報
Leonard bin Abdul Shatar
最高経営責任者
RM2.5k
報酬総額
| CEO給与比率 | 47.8% |
| CEO在任期間 | 16.4yrs |
| CEOの所有権 | n/a |
| 経営陣の平均在職期間 | 3yrs |
| 取締役会の平均在任期間 | 6.3yrs |
経営陣の近況
Recent updates
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Due To Pay A Dividend Of MYR0.005
Aug 27
Duopharma Biotech Berhad (KLSE:DPHARMA) Is Paying Out A Dividend Of MYR0.018
Apr 04Duopharma Biotech Berhad's (KLSE:DPHARMA) Intrinsic Value Is Potentially 24% Below Its Share Price
Feb 17These 4 Measures Indicate That Duopharma Biotech Berhad (KLSE:DPHARMA) Is Using Debt Extensively
Oct 21Duopharma Biotech Berhad (KLSE:DPHARMA) Has Announced A Dividend Of MYR0.005
Aug 18Calculating The Intrinsic Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Aug 07Duopharma Biotech Berhad's (KLSE:DPHARMA) Shareholders Will Receive A Smaller Dividend Than Last Year
Mar 28Calculating The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 27We Think That There Are Issues Underlying Duopharma Biotech Berhad's (KLSE:DPHARMA) Earnings
Nov 26Need To Know: The Consensus Just Cut Its Duopharma Biotech Berhad (KLSE:DPHARMA) Estimates For 2021
Nov 25Duopharma Biotech Berhad's (KLSE:DPHARMA) Dividend Will Be RM0.005
Aug 20Here's Why Duopharma Biotech Berhad (KLSE:DPHARMA) Can Manage Its Debt Responsibly
May 22Duopharma Biotech Berhad (KLSE:DPHARMA) Investors Should Think About This Before Buying It For Its Dividend
Apr 13A Look At The Fair Value Of Duopharma Biotech Berhad (KLSE:DPHARMA)
Mar 14Duopharma Biotech Berhad (KLSE:DPHARMA) Seems To Use Debt Quite Sensibly
Feb 12Do Institutions Own Duopharma Biotech Berhad (KLSE:DPHARMA) Shares?
Jan 28
Is Duopharma Biotech Berhad (KLSE:DPHARMA) The Right Choice For A Smart Dividend Investor?
Jan 12CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | RM45m |
| Dec 31 2023 | RM3k | RM1k | RM53m |
| Sep 30 2023 | n/a | n/a | RM61m |
| Jun 30 2023 | n/a | n/a | RM69m |
| Mar 31 2023 | n/a | n/a | RM72m |
| Dec 31 2022 | RM2m | RM1m | RM70m |
| Sep 30 2022 | n/a | n/a | RM69m |
| Jun 30 2022 | n/a | n/a | RM69m |
| Mar 31 2022 | n/a | n/a | RM68m |
| Dec 31 2021 | RM2m | RM1m | RM66m |
| Sep 30 2021 | n/a | n/a | RM66m |
| Jun 30 2021 | n/a | n/a | RM63m |
| Mar 31 2021 | n/a | n/a | RM63m |
| Dec 31 2020 | RM2m | RM924k | RM59m |
| Sep 30 2020 | n/a | n/a | RM54m |
| Jun 30 2020 | n/a | n/a | RM55m |
| Mar 31 2020 | n/a | n/a | RM54m |
| Dec 31 2019 | RM2m | RM882k | RM55m |
| Sep 30 2019 | n/a | n/a | RM58m |
| Jun 30 2019 | n/a | n/a | RM55m |
| Mar 31 2019 | n/a | n/a | RM51m |
| Dec 31 2018 | RM1m | RM876k | RM48m |
報酬と市場: Leonardの 総報酬 ($USD 537.96 ) は、 MY市場 ($USD 166.06K ) の同様の規模の企業の平均を下回っています。
報酬と収益: Leonardの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Leonard bin Abdul Shatar (59 yo)
16.4yrs
在職期間
RM2,533
報酬
Encik Ariff bin Abdul Shatar, also known as Leonard, has been Group Managing Director of Duopharma Biotech Berhad (alternate name Duopharma Biotech Bhd) since December 28, 2017. Encik bin Abdul Shatar serv...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Group MD & Executive Director | 16.4yrs | RM2.53k | データなし | |
| Chief Financial Officer | 11.9yrs | データなし | 0.000010% MYR 119.3 | |
| Chief Legal Officer & Group Company Secretary | 6.5yrs | データなし | データなし | |
| Chief Compliance Officer | less than a year | データなし | データなし | |
| Chief Manufacturing & Sustainability Officer | 1.7yrs | データなし | 0.00030% MYR 3.6k | |
| Group Head of Risk Management & Integrity | 1.4yrs | データなし | データなし | |
| Chief Executive Officer of Corporate | 1.7yrs | データなし | データなし | |
| Chief Executive Officer of Duopharma Consumer Healthcare Sdn. Bhd. | 4.4yrs | データなし | データなし |
3.0yrs
平均在職期間
55yo
平均年齢
経験豊富な経営陣: DPHARMAの経営陣は 経験豊富 であると考えられます ( 3年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Group MD & Executive Director | 6.5yrs | RM2.53k | データなし | |
| Independent Non-Executive Director | no data | データなし | データなし | |
| Independent Non-Executive Director | 8yrs | RM130.80k | データなし | |
| Non Independent Non Executive Director | 6.3yrs | RM146.40k | 0.0026% MYR 31.4k | |
| Independent Non-Executive Director | 6.5yrs | RM143.80k | データなし | |
| Independent Non-Executive Director | 4.8yrs | RM135.40k | データなし | |
| Independent Non Executive Director | 7.8yrs | RM143.80k | データなし | |
| Senior Independent Non-Executive Director | 7.6yrs | RM141.40k | データなし | |
| Non-Independent & Non-Executive Chairman | less than a year | RM76.70k | データなし | |
| Non Independent & Non Executive Alternate Director | less than a year | データなし | データなし | |
| Non-Independent & Non-Executive Director | less than a year | データなし | データなし |
6.3yrs
平均在職期間
64yo
平均年齢
経験豊富なボード: DPHARMAの 取締役会 は 経験豊富 であると考えられます ( 6.3年の平均在任期間)。